334 related articles for article (PubMed ID: 33181714)
41. Overexpression of AIB1 negatively affects survival of surgically resected non-small-cell lung cancer patients.
He LR; Zhao HY; Li BK; Zhang LJ; Liu MZ; Kung HF; Guan XY; Bian XW; Zeng YX; Xie D
Ann Oncol; 2010 Aug; 21(8):1675-1681. PubMed ID: 20064830
[TBL] [Abstract][Full Text] [Related]
42. Upregulation of amplified in breast cancer 1 contributes to pancreatic ductal adenocarcinoma progression and vulnerability to blockage of hedgehog activation.
Li L; Bao J; Wang H; Lei JH; Peng C; Zeng J; Hao W; Zhang X; Xu X; Yu C; Deng CX; Chen Q
Theranostics; 2021; 11(4):1672-1689. PubMed ID: 33408774
[No Abstract] [Full Text] [Related]
43. The prognostic value of circulating cell-free DNA in breast cancer: A meta-analysis.
Tan G; Chu C; Gui X; Li J; Chen Q
Medicine (Baltimore); 2018 Mar; 97(13):e0197. PubMed ID: 29595655
[TBL] [Abstract][Full Text] [Related]
44. Association of steroid receptor coactivator AIB1 with estrogen receptor-alpha in breast cancer cells.
Azorsa DO; Cunliffe HE; Meltzer PS
Breast Cancer Res Treat; 2001 Nov; 70(2):89-101. PubMed ID: 11768608
[TBL] [Abstract][Full Text] [Related]
45. Clinical significance of AIB1 expression in human breast cancer.
Iwase H; Omoto Y; Toyama T; Yamashita H; Hara Y; Sugiura H; Zhang Z
Breast Cancer Res Treat; 2003 Aug; 80(3):339-45. PubMed ID: 14503806
[TBL] [Abstract][Full Text] [Related]
46. Clinicopathological significance and prognosis of long noncoding RNA SNHG16 expression in human cancers: a meta-analysis.
Jiao R; Jiang W; Wei X; Zhang M; Zhao S; Huang G
BMC Cancer; 2020 Jul; 20(1):662. PubMed ID: 32677912
[TBL] [Abstract][Full Text] [Related]
47. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
48. Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis.
Jiang H; Li H
BMC Cancer; 2021 Feb; 21(1):149. PubMed ID: 33568081
[TBL] [Abstract][Full Text] [Related]
49. TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer.
Stürken C; Möbus V; Milde-Langosch K; Schmatloch S; Fasching PA; Rüschoff J; Stickeler E; Henke RP; Denkert C; Hanker L; Schem C; Vladimirova V; Karn T; Nekljudova V; Köhne CH; Marmé F; Schumacher U; Loibl S; Müller V
BMC Cancer; 2021 Aug; 21(1):920. PubMed ID: 34391399
[TBL] [Abstract][Full Text] [Related]
50. Prognosis difference between HER2-low and HER2-zero breast cancer patients: a systematic review and meta-analysis.
Li C; Yuan Q; Deng T; Xu G; Hou J; Zheng L; Wu G
Breast Cancer; 2023 Nov; 30(6):965-975. PubMed ID: 37470943
[TBL] [Abstract][Full Text] [Related]
51. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients.
Petrelli F; Viale G; Cabiddu M; Barni S
Breast Cancer Res Treat; 2015 Oct; 153(3):477-91. PubMed ID: 26341751
[TBL] [Abstract][Full Text] [Related]
52. Prognostic role of HSF1 overexpression in solid tumors: a pooled analysis of 3,159 patients.
Wan T; Shao J; Hu B; Liu G; Luo P; Zhou Y
Onco Targets Ther; 2018; 11():383-393. PubMed ID: 29398920
[TBL] [Abstract][Full Text] [Related]
53. Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator.
Hudelist G; Czerwenka K; Kubista E; Marton E; Pischinger K; Singer CF
Breast Cancer Res Treat; 2003 Mar; 78(2):193-204. PubMed ID: 12725419
[TBL] [Abstract][Full Text] [Related]
54. Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity.
Reiter R; Oh AS; Wellstein A; Riegel AT
Oncogene; 2004 Jan; 23(2):403-9. PubMed ID: 14691461
[TBL] [Abstract][Full Text] [Related]
55. Prognostic and clinicopathological significance of CD155 expression in cancer patients: a meta-analysis.
Zhang D; Liu J; Zheng M; Meng C; Liao J
World J Surg Oncol; 2022 Oct; 20(1):351. PubMed ID: 36309698
[TBL] [Abstract][Full Text] [Related]
56. The impact of matrix metalloproteinase 2 on prognosis and clinicopathology of breast cancer patients: a systematic meta-analysis.
Chen Y; Wang X; Chen G; Dong C; Zhang D
PLoS One; 2015; 10(3):e0121404. PubMed ID: 25816052
[TBL] [Abstract][Full Text] [Related]
57. Overexpression of an N-terminally truncated isoform of the nuclear receptor coactivator amplified in breast cancer 1 leads to altered proliferation of mammary epithelial cells in transgenic mice.
Tilli MT; Reiter R; Oh AS; Henke RT; McDonnell K; Gallicano GI; Furth PA; Riegel AT
Mol Endocrinol; 2005 Mar; 19(3):644-56. PubMed ID: 15550471
[TBL] [Abstract][Full Text] [Related]
58. The Presence of Tertiary Lymphoid Structures Provides New Insight Into the Clinicopathological Features and Prognosis of Patients With Breast Cancer.
Wang B; Liu J; Han Y; Deng Y; Li J; Jiang Y
Front Immunol; 2022; 13():868155. PubMed ID: 35664009
[TBL] [Abstract][Full Text] [Related]
59. Prognostic Value of β-catenin Expression in Breast Cancer Patients: a Meta-analysis.
Zhang DP; Li XW; Lang JH
Asian Pac J Cancer Prev; 2015; 16(14):5625-33. PubMed ID: 26320427
[TBL] [Abstract][Full Text] [Related]
60. Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue.
List HJ; Reiter R; Singh B; Wellstein A; Riegel AT
Breast Cancer Res Treat; 2001 Jul; 68(1):21-8. PubMed ID: 11678305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
